Annovis Bio, Inc. has a novel approach to addressing chronic and acute neurodegeneration which offers new hope in the fight against the largest unmet need of an aging population

Annovis Bio is developing drugs for alzheimer’s disease and parkinson’s disease, including the orphan indication dementia and alzheimer’s in down syndrome. Our drug attacks neurodegeneration by improving axonal transport, the information highway of the nerve cell, which has been shown to be the cause of nerve cell degeneration and ultimately death.

Industry: Health
Status: Alumni

Contact Information

https://www.annovisbio.com/

maccecchini@annovisbio.com

Maria Maccecchini

CEO

Jeffrey McGroarty

CFO